Head-to-Head trial tests best Second-Line treatment for low platelet disorder
Disease control
Not yet recruiting
This study aims to find out which of two common second-line treatments works better for adults with immune thrombocytopenia (ITP), a condition that causes low platelet counts and bleeding risk. About 220 participants will be randomly assigned to receive either a daily pill (avatr…
Phase: PHASE3 • Sponsor: Ostfold Hospital Trust • Aim: Disease control
Last updated Feb 24, 2026 14:06 UTC